EZH2 and neoplasm: Collectively, these data suggest that full and partial insufficiency for Ezh2 drive distinct phenotypic outcomes in KRAS+/Trp53-null lung adenocarcinomas, with full insufficiency driving more aggressive and metastatic tumors, while partial deficiency generates an anti-tumor immune microenvironment.